koto_feja
MeiraGTx Holdings (NASDAQ:MGTX) added ~14% in the premarket on Tuesday after the New York-based biotech announced promising trial results for its gene therapy candidate AAV-GAD in Parkinson's disease, the second most common neurodegenerative disease in the U.S.
Citing topline data from a
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。